跳至主要内容
临床试验/NCT00398580
NCT00398580已完成2 期

A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism

GlaxoSmithKline8 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2006年10月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
43
试验地点
8
主要终点
Safety measured by: monitoring laboratory tests changes in blood pressure and heart rate and heart activity on an ECG machine

研究概览

简要总结

The combination of testosterone and dutasteride is intended for use in hypogonadal men. This study will evaluate the effect of 28-day repeat dosing of this combination with varying BID doses of testosterone (T), in combination with a fixed BID dose of dutasteride (D), as well as a testosterone alone arm, on T and D levels in the blood. The rationale is to look for the effects of each compound on the other, and to look for any safety problems that may result when the 2 drugs are given together.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Safety measured by: monitoring laboratory tests changes in blood pressure and heart rate and heart activity on an ECG machine

时间窗: days 1 and 28

次要结局

  • Pharmacokinetics of testosterone, DHT, estradiol, estrone & dutasteride(days 1 and 28.)
  • Testosterone concentration .(on days 1 and 28)
  • Anabolic & androgenic Pharmacodynamic biomarkers(pre- and post-dose)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验